Protective effect of budesonide/formoterol compared with formoterol, salbutamol and placebo on repeated provocations with inhaled AMP in patients with asthma: A randomised, double-blind, cross-over study

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Aalbers, René ^a   Boorsma, Martin ^b   van der Woude, Hanneke J ^a   Jonkers, René E ^c  

^a MARTINI HOSPITAL   (Netherlands)

^b ASTRAZENECA   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; PLACEBO; SALBUTAMOL; TERBUTALINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHOCONSTRICTING AGENT; BRONCHODILATING AGENT; BUDESONIDE; ETHANOLAMINE DERIVATIVE; GLUCOCORTICOID;

ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION TEST; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; METERED DOSE INHALER; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; MAXIMAL MID EXPIRATORY FLOW; MIDDLE AGED; MULTICENTER STUDY; NETHERLANDS; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADENOSINE MONOPHOSPHATE; ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHIAL PROVOCATION TESTS; BRONCHOCONSTRICTION; BRONCHOCONSTRICTOR AGENTS; BRONCHODILATOR AGENTS; BUDESONIDE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; MALE; MAXIMAL MIDEXPIRATORY FLOW RATE; MIDDLE AGED; NETHERLANDS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956655754     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-66     Document Type: Article

References (35)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2008, Global Initiative for Asthma (GINA)., http://www.ginasthma.org
2. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999, 13:988-992. 10.1034/j.1399-3003.1999.13e10.x, 10414394.
3. Tattersfield AE, Lofdahl C-G, Postma DS, Eivindson A, Schreurs AG, Rasidakis A. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001, 357:257-261. 10.1016/S0140-6736(00)03611-4, 11214127.
4. Pauwels RA, Sears MR, Campbell M, Villasante C, Huang S, Lindh A. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003, 22:787-794. 10.1183/09031936.03.00055803, 14621086.
5. Cheung D, van Klink HCJ, Aalbers R, . for the OZON study group Improved lung function and symptom control with formoterol on demand in asthma. Eur Respir J 2006, 27:504-510. 10.1183/09031936.06.00006805, 16507849, for the OZON study group.
6. Zetterström O, Buhl R, Mellem H, Hedman J, O'Neill S, Ekstrom T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001, 18:262-268. 10.1183/09031936.01.00065801, 11529282.
7. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, Boulet LP, Naya IP, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004, 20:1403-1418. 10.1185/030079904X2051, 15383189.
8. Boonsawat W, Charoenratanakul S, Pothirat C, Sawanyawisuth K, Seearamroongruang T, Bengtsson T, Brander R, Selroos O. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 2003, 97:1067-1074. 10.1016/S0954-6111(03)00139-2, 14509562.
9. Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharm Ther 2004, 17:89-95.
10. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136. 10.1164/rccm.200407-884OC, 15502112.
11. Rabe KF, Pizzichini E, Ställberg B, Romero S, Balanzat AM, Atienza T. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006, 129:246-256. 10.1378/chest.129.2.246, 16478838.
12. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006, 368:744-753. 10.1016/S0140-6736(06)69284-2, 16935685.
13. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martínez-Jimenez NE, Buhl R. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007, 61:725-736. 10.1111/j.1742-1241.2007.01338.x, 1920547, 17362472.
14. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, Carlsheimer A. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007, 101:2437-2446. 10.1016/j.rmed.2007.07.014, 17905575.
15. Gibson PG. Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers. Eur Respir J 2005, 25:397-399. 10.1183/09031936.05.00002805, 15738278.
16. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma. A randomized controlled trial. Am J Respir Crit Care Med 2001, 163:32-36.
17. Essen-Zandvliet EE, Hop WC, de Jong H, Ferwerda A, Kerrebijn KF. Minor acute effect of an inhaled corticosteroid (budesonide) on bronchial hyperresponsiveness to methacholine in children with asthma. Eur Respir J 1993, 6:383-386.
18. Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled corticosteroids. Eur Respir J 2003, 21:989-993. 10.1183/09031936.03.00072402, 12797493.
19. Aalbers R, Kauffman HF, Koëter GH, Postma DS, de Vries K, de Monchy JGR. Dissimilarity in methacholine and adenosine 5'-monophosphate responsiveness 3 and 24 h after allergen challenge. Am Rev Respir Dis 1991, 144:352-357.
20. Polosa R, Holgate ST. Adenosine bronchoprovocation: a promising marker of allergic inflammation in asthma?. Thorax 1997, 52:919-923. 10.1136/thx.52.10.919, 1758427, 9404382.
21. Ketchell RI, Jensen MW, Spina D, O'Connor BJ. Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine. Eur Respir J 2002, 19:611-616. 10.1183/09031936.02.00332001, 11998988.
22. Aziz I, Wilson AM, Lipworth BJ. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000, 118:1049-1058. 10.1378/chest.118.4.1049, 11035676.
23. Dahlén B, Lantz AS, Ihre E, Skedinger M, Henriksson E, Jörgensen L, Ekström T, Dahlén SE, Larsson K. Effect of formoterol with or without budesonide in repeated low-dose allergen challenge. Eur Respir J 2009, 33(4):747-53. 10.1183/09031936.00095508, 19129280.
24. O'Connor BJ, Ridge SM, Barnes PJ, Fuller RW. Greater effect of inhaled budesonide on adenosine 5'-monophosphate-induced than on sodium-metabisulfite-induced bronchoconstriction in asthma. Am Rev Respir Dis 1992, 146:560-564.
25. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O'Connor BJ. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J Allergy Clin Immunol 2002, 110:603-606. 10.1067/mai.2002.128486, 12373268.
26. Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers JWJ. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J 2004, 23:559-564. 10.1183/09031936.04.00043504, 15083754.
27. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982, 14:377-381.
28. Quanjer P, Tammeling GJ, Cotes JE, Pedersen OF, Yernault JC. Lung volumes and forced ventilatory flows. Report working party: Standardisation of lung function tests European Community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J 1993, 6(Suppl 16):5-40.
29. Vilsvik J, Ankerst J, Palmqvist M, Persson G, Schaanning J, Schwabe G. Protection against cold air and exercise-induced bronchoconstriction while on regular treatment with Oxis. Respir Med 2001, 95:484-490. 10.1053/rmed.2001.1074, 11421506.
30. Duong ML, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 2007, 119:322-327. 10.1016/j.jaci.2006.10.018, 17141859.
31. Boschetto P, Rogers DF, Fabbri LM, Barnes PJ. Corticosteroid inhibition of airway microvascular leakage. Am Rev Respir Dis 1991, 143:605-609.
32. Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J 2006, 27:172-187. 10.1183/09031936.06.00048605, 16387951.
33. Horvath G, Vasas S, Wanner A. Inhaled corticosteroids reduce asthma-associated airway hyperperfusion through genomic and non-genomic mechanisms. Pulm Pharm Ther 2007, 20:157-162.
34. Balanag VM, Yunus F, Yang PC, Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharm Ther 2005, 19:139-147.
35. Bateman ED, Fairal L, Lombardi DM, English R. Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol. Respir Res 2006, 7:13. 10.1186/1465-9921-7-13, 1386666, 16433920.